MCI Issues
Should clinical drug trials in MCI incorporate any special features in their design?
- Comparison of amnestic MCI to generalized MCI
- Must find a way to diagnose in the absence of an observant informant
- Confirmation of hippocampal atrophy, other diffuse atrophy
- Search for other biomarkers (APOE4, serum beta amyloid, etc.)
- Disorder unlikely to be diagnosed quickly in a primary care setting with current techniques